ChiCTR-TRC-11001616 版本V1.1 版本创建时间2015/07/21 19:11:40 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-TRC-11001616 

最近更新日期:

Date of Last Refreshed on:

2015-07-21 19:10:17 

注册时间:

Date of Registration:

2011-10-08 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

右旋美托嘧啶对丙泊酚镇静及丙泊酚负荷瑞芬太尼麻醉效果的影响

Public title:

The effects of dexmedetomidine premedication on propofol sedation and combined propofol with remifentanil anesthsia in Patients Undergoing laryngeal microsurgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

右旋美托嘧啶对丙泊酚镇静及丙泊酚负荷瑞芬太尼麻醉效果的影响

Scientific title:

The effects of dexmedetomidine premedication on propofol sedation and combined propofol with remifentanil anesthsia in Patients Undergoing laryngeal microsurgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘超磊 

研究负责人:

阮祥才 

Applicant:

Leichao Liu 

Study leader:

Xiangcai Ruan 

申请注册联系人电话:

Applicant telephone:

+86 13580507160

研究负责人电话:

Study leader's
telephone:

+86 13760710099

申请注册联系人传真 :

Applicant Fax:

+86 020 81048967

研究负责人传真:

Study leader's fax:

+86 020 81048967

申请注册联系人电子邮件:

Applicant E-mail:

liuchaolei19851219@yahoo.cn

研究负责人电子邮件:

Study leader's E-mail:

xc_ruan@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

http://www.81ts.com

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

http://www.81ts.com

申请注册联系人通讯地址:

广东省广州市越秀区盘福路1号麻醉科

研究负责人通讯地址:

广东省广州市越秀区盘福路1号麻醉科

Applicant address:

1 Panfu Road, Guangzhou, Guangdong

Study leader's address:

1 Panfu Road, Guangzhou, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

510180

研究负责人邮政编码:

Study leader's postcode:

510180

申请人所在单位:

广州市第一人民医院麻醉科

Applicant's institution:

Dept. of Anesthesiology, Guangzhou 1st People's Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

011

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

广州市第一人民医院伦理委员会

Name of the ethic committee:

The ethic committee of Guangzhou 1st People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2011-05-31 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州市第一人民医院麻醉科

Primary sponsor:

Dept. of Anesthesiology, Guangzhou 1st People's Hospital

研究实施负责(组长)单位地址:

广东省广州市越秀区盘福路1号麻醉科

Primary sponsor's address:

1 Panfu Road, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

GUANGDONG

City:

单位(医院):

广州市第一人民医院

具体地址:

广东省广州市越秀区盘福路1号

Institution
hospital:

Guangzhou 1st People's Hospital

Address:

1 Panfu Road, Guangzhou, Guangdong

经费或物资来源:

广州市第一人民医院

Source(s) of funding:

Guangzhou 1st People's Hospital

研究疾病:

声带息肉  

Target disease:

Vocal cord polyp

研究疾病代码:

J38.102

Target disease code:

J38.102

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

III期临床试验 

Study phase:

3

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

研究右旋美托嘧啶对丙泊酚镇静及丙泊酚复合瑞芬太尼全凭静脉麻醉效应的影响  

Objectives of Study:

To study the effects of dexmedetomidine premedication on propofol sedation and combined propofol with remifentanil anesthsia in Patients Undergoing laryngeal microsurgery.

药物成份或治疗方案详述:

盐酸右旋美托嘧啶 

Description for medicine or protocol of treatment in detail:

dexmedetomidine 

纳入标准:

ASAI级择期行支撑喉镜下声带息肉摘除手术的患者,年龄18~55岁,体重指数<30。

Inclusion criteria

The patient who are ASAI and ready for undergoing laryngeal microsurgery. At the same time the age of the patient must between 18 to 60 and the BMI must be less than 30.

排除标准:

1.困难插管,2.高血压病史3.严重心肺疾病4.近期用过α2受体激动剂或拮抗剂的患者。

Exclusion criteria:

The patient complicated with
1. Difficult intubation;
2. Hypertension;
3. Heart and lung disease;
4. Consumption of alpha 2 adrenergic agonist or Antagonist recently, will be excluded.

研究实施时间:

Study execute time:

From 2011-05-31 00:00:00 To 1990-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2011-05-31 00:00:00 To 2011-12-30 00:00:00

干预措施:

Interventions:

组别:

P

样本量:

25

Group:

P

Sample size:

干预措施:

麻醉诱导前预注生理盐水

干预措施代码:

Intervention:

Pre-injection of saline before induction of anesthesia

Intervention code:

组别:

D1

样本量:

25

Group:

D1

Sample size:

干预措施:

麻醉诱导前预注0.25ug/kg右旋美托嘧啶

干预措施代码:

Intervention:

Pre-injection of 0.25ug/kg dexmedetomidine before induction of anesthesia

Intervention code:

组别:

D2

样本量:

25

Group:

D2

Sample size:

干预措施:

麻醉诱导前预注0.5ug/kg右旋美托嘧啶

干预措施代码:

Intervention:

Pre-injection of 0.5ug/kg dexmedetomidine before induction of anesthesia

Intervention code:

组别:

D3

样本量:

25

Group:

D3

Sample size:

干预措施:

麻醉诱导前预注1.0ug/kg右旋美托嘧啶

干预措施代码:

Intervention:

Pre-injection of 1.0ug/kg dexmedetomidine before induction of anesthesia

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

GuangZhou

单位(医院):

广州市第一人民医院 

单位级别:

市级三甲 

Institution
hospital:

Guangzhou No.1 People's Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

镇静评分

指标类型:

主要指标

Outcome:

Narcotrend Index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

主要指标

Outcome:

heart rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

丙泊酚靶浓度

指标类型:

主要指标

Outcome:

Target concentration of propofol

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

主要指标

Outcome:

Blood Pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

瑞芬太尼靶浓度

指标类型:

次要指标

Outcome:

Target concentration of remifentani

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Table of random number

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

受试者和研究者

Blinding:

research subjects and researcher

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

广州市第一人民医院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Guangzhou No.1 People's Hospital

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

广州医学院

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Guangzhou Medical University

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-07-21 19:10:17